Markets Edge

ReadingBiotech M&A just got faster. Founders still in process should read the new timeline: antitrust clears in weeks, not months. Pricing reflects it.

ReadingGilead just signaled the deal closes on schedule. No regulatory surprises. Other biopharma buyers watching know the approval playbook just accelerated.

ReadingEducational publishing has stabilized. Scholastic's capital allocation now favors buybacks over expansion. That's the signal that margin improvement is locked in.

ReadingSenior living M&A remains active. Selectis shareholders will evaluate the offer against operational synergies Black Pearl brings. The premium will reflect integration risk.

ReadingLuxury demand is reverting to pre-pandemic behavior. The Middle East supercycle is over. Kering and Hermès will face the same questions. Expect them to guide lower.

ReadingLuxury brands must now compete on brand depth, not distribution speed. That favors heritage players with pricing power. Everyone else discounts into the reset.

ReadingWatch the allocation. If pension funds are buying TSMC, they expect years of consistent demand. The Micron facility signals government confidence in U.S. fab economics. Both can be true.